玮俊生物科技年度收入约3.7亿港元 同比减少52.2%

格隆汇
20 Dec 2024

格隆汇12月20日丨玮俊生物科技(00660.HK)公告,截至2024年6月30日止年度,集团录得收入约370.0百万港元,较上一年度减少52.2%。收入下降主要归因于报告期内变性淀粉及其他生化产品的市场需求疲软及消费量下降。此外,作为提升整体营运效率的战略重组的一部分,集团已停止某些表现不佳的产品线。这一决定亦导致收入大幅下降。公司拥有人应占亏损截至2024年6月30日止年度约为44.2百万港元...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10